Cytokinetics Soars as Heart Drug Hits Goal in Late-Stage Trial bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in JAMA Cardiology Topline data announced from Phase 3 trial of TP-03 in Chinese Demodex blepharitis patientsCash, cash equivalents and marketable securities of $252.2 million as of September 30, 2023Strategic review ongo
Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at.
LianBio (NASDAQ: LIAN) shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb (NYSE: BMY) to purchase LianBio's exclusive rights to develop and commercialize